Department of Neurosurgery, Gamma Knife Center, Komaki City Hospital, Komaki, Japan.
Neurosurgery. 2010 Apr;66(4):688-94; discussion 694-5. doi: 10.1227/01.NEU.0000367554.96981.26.
To determine the limiting dose to the optic apparatus in single-fraction irradiation in patients with craniopharyngioma treated with gamma knife radiosurgery (GKRS).
One hundred patients with 109 craniopharyngiomas treated with GKRS were evaluated with a median follow-up period of 68 months. Tumor volume varied from 0.1 to 36.0 (median, 3.3) cm. Marginal doses varied from 10 to 18 (median, 11.4) Gy. Maximum dose to any part of the optic apparatus varied from 2 to 18 (median, 10) Gy.
The actuarial 5- and 10-year overall rates of survival of tumor progression after GKRS were 93% and 88%, respectively. Similarly, the actuarial 5- and 10-year progression-free survival rates were 62% and 52%, respectively. Among 94 patients in whom visual function was evaluable after GKRS, only 3 patients developed radiation-induced optic neuropathy, indicating an overall Kaplan-Meier radiation-induced optic neuropathy rate of 5%. Of these patients, 2 received 15 Gy or greater to the optic apparatus. Another patient who received 8 Gy or less had undergone previous fractionated radiation therapy with a biologically effective dose of 60 Gy.
The optic apparatus seems to be more tolerant of irradiation than previously thought. Careful dose planning is essential, particularly in patients who underwent prior external beam radiation therapy.
确定接受伽玛刀放射外科治疗的颅咽管瘤患者单次分割照射时视神经器的限光剂量。
对 100 例 109 个颅咽管瘤患者进行评估,中位随访时间为 68 个月。肿瘤体积为 0.1 至 36.0cm³(中位数为 3.3cm³)。边缘剂量为 10 至 18Gy(中位数为 11.4Gy)。视神经器任何部位的最大剂量为 2 至 18Gy(中位数为 10Gy)。
GKRS 后肿瘤进展的 5 年和 10 年总生存率分别为 93%和 88%。同样,5 年和 10 年无进展生存率分别为 62%和 52%。在 94 例可评估 GKRS 后视力功能的患者中,仅 3 例发生放射性视神经病变,表明总体 Kaplan-Meier 放射性视神经病变发生率为 5%。其中 2 例患者接受了 15Gy 或更大剂量的视神经照射。另一位接受 8Gy 或更少剂量照射的患者曾接受过 60Gy 生物有效剂量的分次放射治疗。
视神经器似乎比以前认为的更能耐受照射。需要仔细的剂量规划,特别是对于那些曾接受过外部束放疗的患者。